We use cookies to ensure you get the best experience on our website. Learn more about our privacy policy.
Attention
This is an external link. Click “OK” to continue.
Our second pipeline drug is designed to be a strong, non-addictive analgesic
ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen, an NSAID prescribed for a range of pain indications. While ketoprofen is one of the most GI-damaging NSAIDs, ATB-352 has been shown to be gastrointestinal-safe in animal studies. Investigational New Drug ("IND")-enabling studies are underway.
Attractive Indication with Strong IP
Antibe has identified a specialized pain indication with a significant unmet medical need for which few therapies exist. We expect to release further information about this indication once a patent application has been filed. If granted, ATB-352 will benefit from IP protection in major markets into the 2040s.
Non-Addictive and Gastrointestinal-Safe
In preclinical studies, ATB-352 caused negligible gastrointestinal (“GI”) damage compared to ketoprofen alone, despite comparable suppression of intestinal prostaglandin or whole blood thromboxane synthesis.1 Rats were treated orally twice-daily for five days with either 10 mg/kg of ketoprofen, or an equimolar dose of ATB-352 of 14.5 mg/kg. (See results in accompanying graph.)
When tested over a concentration range of 3 to 30 µg/mL, no agonist effect was found against the opioid receptor, indicating that ATB-352 has no addiction potential.2
ATB-352 causes negligible gastrointestinal damage in rats
compared to ketoprofen.
Enhanced Analgesic Potency and GI Safety Confirmed
In 2020, results were published demonstrating that ATB-352 induces significantly more potent and effective analgesia than ketoprofen in a well characterized animal model of surgical pain.3 Despite the increased pain reduction, ATB-352 was much better tolerated in the GI tract; mice receiving ketoprofen exhibited a dose-dependent increase in the severity of bleeding ulcers in the stomach and intestine. In contrast, no GI damage was observed in mice treated with ATB-352, even at very high doses.3
A mechanism of action was also identified that explains the increased pain-killing effects. In addition to blocking the production of pain-promoting prostaglandins, ATB-352 further reduced pain by significantly elevating the levels of naturally-occurring endocannabinoids in comparison to the levels of endocannabinoids observed in mice treated with ketoprofen alone.3
……………………………………
1. Gemici et al. H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide. 2015 Apr 30;46:25-31.
2. Antibe pre-clinical data on ATB-352.
3. Costa et al. Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti- Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids. Antioxidant and Redox Signaling. 2020 Feb 16.